益丰药房
(603939)
| 流通市值：287.05亿 | | | 总市值：287.10亿 |
| 流通股本：12.12亿 | | | 总股本：12.12亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,009,043,521.27 | 24,062,154,701.73 | 17,218,897,862.76 | 11,762,401,111.51 |
| 营业收入 | 6,009,043,521.27 | 24,062,154,701.73 | 17,218,897,862.76 | 11,762,401,111.51 |
| 二、营业总成本 | 5,391,078,498.36 | 21,973,892,618.65 | 15,712,009,022.92 | 10,676,892,508.96 |
| 营业成本 | 3,627,192,865.13 | 14,408,310,539.42 | 10,263,836,853.11 | 7,051,612,477.93 |
| 税金及附加 | 22,824,215.56 | 95,485,533.5 | 69,011,236.33 | 48,210,499.54 |
| 销售费用 | 1,413,763,705.15 | 6,179,375,830.54 | 4,475,400,595.82 | 3,005,586,267.14 |
| 管理费用 | 279,180,393.48 | 1,082,881,741.13 | 756,145,104.2 | 481,533,402.41 |
| 研发费用 | 6,821,657.73 | 33,935,812.25 | 25,185,648.1 | 16,865,821.99 |
| 财务费用 | 41,295,661.31 | 173,903,161.81 | 122,429,585.36 | 73,084,039.95 |
| 其中:利息费用 | 54,675,521.2 | 221,373,934.51 | 159,590,829.88 | 102,736,750.31 |
| 其中:利息收入 | 19,865,240.25 | 72,647,179.88 | 55,481,384.79 | 42,021,674.55 |
| 加:投资收益 | 27,186,162.03 | 108,128,784.49 | 76,803,405.41 | 49,447,044.49 |
| 资产处置收益 | 16,762,834.75 | 49,938,810.67 | 22,817,878.75 | 14,952,132.95 |
| 资产减值损失(新) | -22,763,668.03 | -102,396,476.85 | -59,754,324.5 | -38,797,603.61 |
| 信用减值损失(新) | -2,583,788.33 | 2,154,986.62 | -2,153,705.2 | -526,562.83 |
| 其他收益 | 13,975,298.59 | 57,736,157.07 | 40,942,345.23 | 23,383,714.37 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 650,541,861.92 | 2,203,824,345.08 | 1,585,544,439.53 | 1,133,967,327.92 |
| 加:营业外收入 | 1,576,318.95 | 12,735,226.42 | 8,127,203.89 | 5,411,664.44 |
| 减:营业外支出 | 4,289,327.1 | 34,112,189.78 | 13,679,482.67 | 7,882,548.33 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 647,828,853.77 | 2,182,447,381.72 | 1,579,992,160.75 | 1,131,496,444.03 |
| 减:所得税费用 | 154,279,572.7 | 529,665,095.86 | 381,573,694.73 | 271,425,909.71 |
| 六、净利润 | 493,549,281.07 | 1,652,782,285.86 | 1,198,418,466.02 | 860,070,534.32 |
| 持续经营净利润 | 493,549,281.07 | 1,652,782,285.86 | 1,198,418,466.02 | 860,070,534.32 |
| 归属于母公司股东的净利润 | 449,493,528.8 | 1,528,576,669.36 | 1,110,500,691.55 | 797,718,135.2 |
| 少数股东损益 | 44,055,752.27 | 124,205,616.5 | 87,917,774.47 | 62,352,399.13 |
| (一)基本每股收益 | 0.37 | 1.26 | 0.92 | 0.66 |
| (二)稀释每股收益 | 0.36 | 1.24 | 0.92 | 0.66 |
| 八、其他综合收益 | 9,609,750 | -69,190,200 | -89,370,675 | -119,801,550 |
| 归属于母公司股东的其他综合收益 | 9,609,750 | -69,190,200 | -89,370,675 | -119,801,550 |
| 九、综合收益总额 | 503,159,031.07 | 1,583,592,085.86 | 1,109,047,791.02 | 740,268,984.32 |
| 归属于母公司股东的综合收益总额 | 459,103,278.8 | 1,459,386,469.36 | 1,021,130,016.55 | 677,916,585.2 |
| 归属于少数股东的综合收益总额 | 44,055,752.27 | 124,205,616.5 | 87,917,774.47 | 62,352,399.13 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |